During the discussion and exchange, the two sides conducted in-depth exchanges and discussions on the construction status quo, scientific research cooperation, clinical practice, talent training, core team construction and other aspects. Chairman Shi Yuan expressed high concern and interest in the achievements of the hematology department of Union Shenzhen Hospital in CAR T cell therapy. Chairman Shi Yuanyuan proposed that as a major public service platform for Shenzhen's biomedical industry, Shenzhen Cell Valley has advanced cell preparation technology and strict quality management system, which can meet the requirements of GMP and ensure the safety and effectiveness of cell products. At the same time, it can provide personnel training support and scientific research technical support for the hematology department of XIEHE Shenzhen Hospital. Shenzhen Cell Valley team attaches great importance to cooperation with clinical institutions, and hopes to establish a deeper cooperative relationship with the hematology department of XIEhe Shenzhen Hospital to jointly promote the development and application of cell therapy.

Director Guo Zhi warmly welcomed the visit of Shenzhen Cell Valley and stressed the importance of the close combination of scientific research and clinical practice in improving the treatment effect and promoting the development of the discipline. And said that the hematology department has a first-class professional team in Shenzhen, as one of the departments that treat the most blood patients in Shenzhen, with rich clinical experience and clinical data, we hope that through the comprehensive and in-depth cooperation with Shenzhen Cell Valley, we can further promote the clinical research and clinical practice of cell therapy for blood diseases, and provide better medical services for patients.

Through in-depth cooperation, the two parties will jointly carry out clinical research and clinical application of CAR T cell therapy in different types of blood diseases, improve the therapeutic effect, provide more treatment options for patients, and make greater contributions to the development of the field of cell therapy.